Save time and lower costs when enrolling patients in clinical trials.
According to a report by the Tufts Center for the Study of Drug Development (Tufts CSDD), 48% of clinical trial sites fail to meet enrollment targets. The majority of sites suffer through under-enrollment while 11% fail to enroll a single patient. The costs are staggering. Each failed site costs the trial sponsor approximately $50,000 and each day of delay in patient enrollment can cost millions of dollars.
Acuitas Lighthouse and Acuitas AMR Gene Panel can reduce costs and increase the efficiency of antimicrobial clinical trials. By providing a means to identify drug-resistant microbes quickly and to survey the prevalence of antimicrobial resistance, ideal sites that will meet or exceed recruitment targets can be identified and prioritized. Patient enrollment decisions can be made within hours translating to faster trial completion. The real-time data collected and maintained by Acuitas Lighthouse helps ensure that only sites and patients with the right criteria are selected, smoothing the road to commercialization of new antibiotics.